Multidrug co-crystals: towards the development of effective therapeutic hybrids

Download Type: Adobe PDF

This review emphasizes those multidrug co-crystals that could find potential applications in the treatment of various diseases and in the development of cost-effective hybrid therapeutics.

Co-crystals have garnered the interest of the pharmaceutical industry with the introduction of regulatory guidelines by the US Food and Drug Administration (FDA) as a result of expanded patent portfolios. The Phase II clinical success of tramadol and celecoxib co-crystal for the treatment of acute pain followed by a recent reflection paper published by the European Medicines Agency (EMA) have

further boosted the development of drug–drug co-crystals. Here, we shed light on the developments of drug–drug co-crystals and highlight future perspectives for exploring new therapeutic hybrids deploying drug–drug, drug–nutraceuticals and drug–inorganic salt combinations with improved pharmaceutical and biopharmaceutical performance.

Share this download

More services